Crossmark

A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial

Crossref DOI link: https://doi.org/10.1186/s12884-020-03481-y

Published Online: 2021-01-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hague, William M. https://orcid.org/0000-0002-5355-2955
Callaway, Leonie

Chambers, Jennifer

Chappell, Lucy

Coat, Suzette

de Haan-Jebbink, Jiska

Dekker, Marloes

Dixon, Peter

Dodd, Jodie

Fuller, Maria

Gordijn, Sanne

Graham, Dorothy

Heikinheimo, Oskari

Hennessy, Annemarie

Kaaja, Risto

Khong, Teck Yee

Lampio, Laura

Louise, Jennie

Makris, Angela

Markus, Corey

Marschall, Hanns-Ulrich

Middleton, Philippa

Mol, Ben W.

Morris, Jonathan

Newnham, John P.

Ovadia, Caroline

Peek, Michael

Shand, Antonia

Stark, Michael

Thornton, Jim

Timonen, Susanna

Walker, Susan

Warrilow, David

Williamson, Catherine
Funding

Funding for this research was provided by:

Department of Health, Australian Government (MRFF APP1152418)
License Information

Text and Data Mining valid from 2021-01-12

Version of Record valid from 2021-01-12
More Information

Article History

Received: 27 October 2020

Accepted: 4 December 2020

First Online: 12 January 2021

Ethics approval and consent to participate

: Primary ethical approval for the Protocol and the Patient information and consent form has been provided by the Women’s and Children’s Hospital Network Human Research Ethics Committee: reference HREC/18/WCHN/36. Written informed consent will be obtained from each participant prior to her undertaking any study procedures.

: Not applicable.

: JC, PD, H-UM, CO and CW consult for Mirum Pharmaceuticals, H-UM consults for Metabogen, CW consults for GlaxoSmithKlein.

Document is current

Any future updates will be listed below